Frontline Alecensa Extends Survival in Advanced ALK-Positive Lung Cancer

1 month ago 26

Alecensa cut the risk of death by 22% versus Xalkori, with median overall survival reaching 81.1 months versus 54.2 months in advanced ALK-positive lung cancer.

1. Homepage
2. Lung Cancer
3. Frontline Alecensa Extends Survival in Advanced ALK-Positive Lung Cancer